VitroGenLabs Hungary Kft.

Overview

VitroGenLabs Hungary Kft. is a contract research organization founded in 2024, dedicated to advancing regulatory science through validated in vitro toxicology methods. The organization specializes in non-animal testing alternatives (new approach methodologies, or NAMs) for safety assessment across pharmaceutical, cosmetic, chemical, and medical device sectors.

Core Services

Validated In Vitro Assays:

• OECD TG 431 (In Vitro Skin Corrosion using EpiDerm™ reconstructed human epidermis with MTT viability assay) — discriminates corrosive vs. non-corrosive substances and supports UN GHS sub-categorization (Category 1A and 1B/1C)
• OECD TG 439 (In Vitro Skin Irritation using EpiDerm™ RhE model) — distinguishes UN GHS Category 2 irritants from non-irritants
• OECD TG 435 (In Vitro Membrane Barrier Test using CORROSITEX® assay) — bioengineered membrane system suited for organic acids, bases, and surfactants; results within 24 hours
• OECD TG 492B (Reconstructed Human Corneal Epithelium using SkinEthic™ HCE model) — assesses corneal epithelial cytotoxicity and discriminates UN GHS categories (No Category, Category 2, Category 1)

Emerging Assays in Active Deployment:

• Endocrine disruption screening (ER-CALUX®, VM7Luc4E2 cell lines for estrogen receptor agonism/antagonism; AR-EcoScreen™ for androgen receptor assays; competitive binding assay with full-length recombinant hERα)
• Haemocompatibility testing (platelet and leukocyte quantification, thrombosis assessment via TEG, coagulation PT/aPTT, complement activation C3a/SC5b-9, platelet activation)
• Medical device biocompatibility (MTT, neutral red uptake, colony formation assays; RHE and RCE irritation models for device extracts and materials per ISO 10993-23)

Regulatory Compliance & Quality

• GLP Accreditation: Issued by the Hungarian GLP Monitoring Authority (NNGYK); all studies conducted under OECD Principles of Good Laboratory Practice
• Quality Management: ISO 9001:2015 certified
• Regulatory Acceptance: Methods validated by EURL ECVAM and recommended by ICCVAM; study reports formatted for ECHA, EMA, FDA, and EFSA submissions
• Regulatory Frameworks: Compliant with EU REACH, CLP, EU Cosmetics Regulation 1223/2009, and FDA IND-enabling requirements

Differentiation

VitroGenLabs emphasizes the 3Rs principles (Replace, Reduce, Refine) and positions non-animal toxicology as the future of regulatory science rather than a compromise. The organization offers faster turnaround and reduced costs compared to traditional in vivo testing, aligned with regulatory shifts including upcoming REACH revisions and the FDA Modernization Act 2.0.

Team Expertise

The organization is led by experienced toxicologists with 30+ years of combined expertise:

• In Vitro Study Director: 13+ years in in vitro toxicology; managed ~1,000 GLP and non-GLP studies; expertise in EpiSkin, EpiDerm, EpiOcular, SkinEthic TTT, EpiOral, EpiGingival, and AMES mutagenicity testing
• Study Director / Clinical Pathology Scientist: 10+ years in preclinical safety assessment and clinical pathology; GLP-compliant study expertise in hematology, clinical chemistry, coagulation, and hormone analysis (T3, T4, TSH); method development and validation experience